These forward looking statements include read more.

This press release may contain certain forward-looking statements based on Sangamo ‘s current expectations. These forward looking statements include, without limitation, references to the clinical trials of SB-509, the research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo the ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including the uncertainties associated with the initiation and completion of stages of the SB-509 – study whether the SB-509 clinical study validated and support tolerability and efficacy of SB-509, technological challenges, Sangamo ability to commercially viable products and technological developments by our competitors develop read more . See the Company’s SEC filings, and in particular the risk factors described the company’s Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences assumes no the the forward-looking information contained in this press release.

About SangamoSangamo BioSciences, concentrated focus on the discovery and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic development programs are currently in Phase 1 clinical trials for evaluation of safety in patients with diabetic neuropathy and peripheral arterial disease. Other therapeutic development programs are based on macular degeneration, ischemic heart disease, congestive heart failure, neuropathic pain, and infectious and monogenic disease focused. Sangamo core competencies enable the construction of a class of DNA-binding proteins, such as zinc-finger DNA-binding proteins are known. By engineering ZFPs has created. DNA sequence see Sangamo ZFP transcription factors ), which can control the expression of genes and thus cell function has created. Sangamo is also developing sequence-specific ZFP Nucleases ) for therapeutic gene modification as a treatment for a variety of monogenic diseases such as sickle cell anemia, and for infectious diseases such as HIV. Sangamo has several Enabling Technology Agreements with companies to apply its ZFP established established to enhance the production of protein pharmaceuticals. For more information about Sangamo the the company website.

The FDA approved a nasal age on the basis of out of three studies of more than 6,000 children aged 6 to 59 months.